Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 14, Number 3—March 2008

Research

Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel

Isaac Levy*1, Galia Grisaru-Soen*12, Liat Lerner-Geva†, Eitan Kerem‡, Hana Blau§, Lea Bentur¶, Micha Aviram#, Joseph Rivlin**, Elie Picard††, Anita Lavy‡‡, Yakov Yahav*, and Galia Rahav*Comments to Author 
Author affiliations: *Sheba Medical Center, Tel Hashomer, Israel; †Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer, Israel; ‡Hadassah Hebrew University Hospital, Jerusalem, Israel; §Schneider Children’s Medical Center of Israel, Petah Tikva, Israel; ¶Rambam Medical Center, Haifa, Israel; #Soroka University Hospital, Beer Sheva, Israel; **Carmel Medical Center, Haifa, Israel; ††Shaare Zedek Medical Center, Jerusalem, Israel; ‡‡Mycobacterium Reference Laboratory of Israel, Tel Aviv, Israel; 1These authors contributed equally to this work.; 2Current affiliation: Dana Children’s Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.;

Main Article

Table 3

Comparison of patients and controls in univariate and multivariate analyses*

Parameter Patients (n = 42) Controls (n = 144) p value Adjusted OR 95% CI
Age, y (mean ± SD) 24.2 ± 10.9 19.4 ± 10.0 0.014 1.03 0.99–1.09
Sex, F/M 18/24 56/88 0.64
No. sputum specimens (mean ± SD) 5.7 ± 4.8 2.4 ± 1.7 <0.0001 1.47 1.17–1.85
Hemoptysis 10 12 0.006 1.08 0.29–4.05
FEV1, L/s (mean ± SD) 56.7 ± 19.6 71.2 ± 21.8 0.0001 0.97 0.94–0.99
Pancreatic insufficiency 35 100 0.07
Sweat chloride, Meq/ L (mean ± SD) 73.1 ± 50.2 66.2 ± 48.3 0.43
Hospitalization, d (mean ± SD) 33.2 ± 37.5 18.4 ± 24.5 0.019 0.99 0.97–1.01
Administration of antimicrobial drugs, d (mean ± SD) 49.9 ± 78.7 14.7 ± 29.4 0.007 0.99 0.98–1.00
Azithromycin treatment 30 74 0.02 1.00 0.99–1.00
Azithromycin treatment, d (mean ± SD) 367.6 ± 302.7 221.9 ± 288.4 0.007 1.00 0.99–1.00
Ibuprofen treatment 5 2 0.001 4.72 0.60–36.85
Insulin treatment 4 13 0.92
Systemic steroids treatment 3 10 0.96
Inhaled steroids treatment 26 70 0.13
Pseudomonas aeruginosa 40 94 0.0005 0.76 0.32–1.79
Staphylococcus aureus 18 58 0.95
Aspergillus spp. 28 31 <0.0001 5.14 1.87–14.11
Allergic bronchopulmonary aspergillosis 3 3 0.10
Haemophillus influenza 3 24 0.13
Alcaligenes xylosoxidans 0 5 0.22
Klebsiella pneumoniae 3 4 0.17
Stenotrophomonas maltophilia 2 3 0.34

*OR, odds ratio; CI, confidence interval; SD, standard deviation; FEV1, forced expiratory volume in 1 s.

Main Article

1These authors contributed equally to this work.

2Current affiliation: Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO